Intec Pharma announces clinical trial failure after finding new drug did not have a market difference treating PD from existing medications.
Kenny Walter
Advertisement
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Articles by Kenny Walter
New research shows keeping a diary while in the ICU does not prevent PTSD symptoms from occurring.
Several new generics available to treat neuropathic pain linked to diabetic peripheral neuropathy, fibromyalgia partial onset seizures, and other conditions.
New method in reporting P values adjusts for multiplicity to more accurately reflect meaningful statistics.
A new study links high levels of high‐sensitivity cardiac troponin T and N‐terminal pro‐B‐type natriuretic peptide to an increase in fall risk for geriatric adults.
The meta-analysis was comprised of 402 individual studies in which the primary therapy was 1 of 32 antipsychotics.
The Erchonia Corp. product reportedly reduced patient pain by nearly 50% in clinical trials.
New evidence from a cumulative RCT analysis suggests irritable bowel syndrome patients do not definitively benefit from FMT treatment.
The majority of physicians who exhibit burnout symptoms receive more than the average number of system-generated in-basket messages.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
OMA 2026 Recap: GLP-1s in Conditions Beyond Obesity
3
OMA 2026 Recap: The Side Effects of GLP-1s for Obesity
4
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
5